GMP violations prompt U.S. FDA warning against 2 Indian drugmakers

08/25/2013 | Economic Times (India), The

Indian drugmakers Posh Chemicals and Promed Exports received warning letters from the U.S. FDA that indicated breaches in good manufacturing practices. Six India-based drug facilities have received the notices in the past three months. Lupin Pharma CEO Vinita Gupta said "all the FDA is trying to do is differentiate the good manufacturers from the not-so-good ones. Indian manufacturers are not being targeted."

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL